AIM: To observe the efficacy of Conbercept for different types of macular edema after cataract surgery with diabetes.

METHODS: Totally 52 cases(52 eyes)of macular edema(ME)patients after cataract surgery with diabetes were selected between Jan 2017 and Dec 2018. According to the morphologies of ME through optical coherence tomography(OCT), patients were divided into 3 groups, diffuse retinal thickening(DRT group)with 18 cases(18 eyes), cystoid macular edema(CME group)with 20 cases(20 eyes)and serous retinal detachment(SRD group)with 14 cases(14 eyes). All the patients received intravitreal injection of Conbercept by using 1+PRN method and followed up for 12mo after treatment. The best corrected visual acuity(BCVA)and central macular thickness(CMT)and injection times were recorded and compared.

RESULTS: Before treatment, the differences of BCVA and CMT among 3 groups were not statistically significant, while the course of ME in DRT group was shorter than CME group and SRD group(P<0.05). 1mo after treatment, the BCVA and CMT in 3 groups were improved significant, and beginning at 3mo, the BCVA and CMT in 3 groups were continue to improve and stabilize, they were improved significant compared with before treatment(P<0.05). 1mo, 3mo, 6mo and 12mo after treatment, the BCVA and CMT in DRT group and CME group is better than SRD group(P<0.05), while the BCVA and CMT among DRT group and CME group were not statistically significant(P>0.05). The injection times in 3 groups was 3.2±0.9, 2.9±0.8 and 4.1±1.1, the injection times in SRD group was the most frequent in 3 groups(P<0.05).

CONCLUSION: ME after cataract surgery with diabetes should be treated early. Conbercept could improve BCVA and CMT in different types of ME after cataract surgery with diabetes effectively.